Monitoring initial response to Angiotensin-converting enzyme inhibitor-based regimens: an individual patient data meta-analysis from randomized, placebo-controlled trials

Hypertension
Katy J L BellLes Irwig

Abstract

Most clinicians monitor blood pressure to estimate a patient's response to blood pressure-lowering therapy. However, the apparent change may not actually reflect the effect of the treatment, because a person's blood pressure varies considerably even without the administration of drug therapy. We estimated random background within-person variation, apparent between-person variation, and true between-person variation in blood pressure response to angiotensin-converting enzyme inhibitors after 3 months. We used meta-analytic mixed models to analyze individual patient data from 28 281 participants in 7 randomized, controlled trials from the Blood Pressure Lowering Trialists Collaboration. The apparent between-person variation in response was large, with SDs for change in systolic blood pressure/diastolic blood pressure of 15.2/8.5 mm Hg. Within-person variation was also large, with SDs for change in systolic blood pressure/diastolic blood pressure of 14.9/8.45 mm Hg. The true between-person variation in response was small, with SDs for change in systolic blood pressure/diastolic blood pressure of 2.6/1.0 mm Hg. The proportion of the apparent between-person variation in response that was attributed to true between-person variation w...Continue Reading

References

Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsG Dagenais
Sep 19, 2003·Lancet·K M Fox, UNKNOWN EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators
Nov 15, 2003·Lancet·Fiona Turnbull, UNKNOWN Blood Pressure Lowering Treatment Trialists' Collaboration
Dec 6, 2003·Hypertension·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Oct 20, 2004·Circulation·Folkert W AsselbergsUNKNOWN Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators
Nov 2, 2004·The New England Journal of Medicine·Piero RuggenentiUNKNOWN Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators
Nov 9, 2004·The New England Journal of Medicine·Eugene BraunwaldUNKNOWN PEACE Trial Investigators
Nov 14, 2006·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Tom Marshall
Feb 16, 2008·BMJ : British Medical Journal·Katy J L BellPetra Macaskill
Dec 26, 2008·Journal of Clinical Epidemiology·Katy J L BellLes Irwig

❮ Previous
Next ❯

Citations

Apr 18, 2014·Journal of Human Hypertension·F GueyffierUNKNOWN IDEAL Trial Group
Aug 10, 2012·Thérapie·Theodora Bejan-AngoulvantUNKNOWN IDEAL Study Group
Jun 21, 2015·Contemporary Clinical Trials·Mark SimmondsLesley Stewart
Apr 30, 2015·Journal of Hypertension·Cristina Menni
Jul 16, 2013·Seminars in Immunology·Luis A BritoDerek T O'Hagan
Sep 29, 2011·European Journal of Preventive Cardiology·Katy BellLes Irwig
Dec 22, 2016·British Journal of Clinical Pharmacology·Sergei I PetrykivHiddo J L Heerspink
Sep 29, 2018·Upsala Journal of Medical Sciences·Johan SundströmOllie Östlund
Dec 20, 2011·Journal of Hypertension·Geoffrey A HeadAlison Wilson
Jul 1, 2015·European Heart Journal. Quality of Care & Clinical Outcomes·Johan Sundström, Bruce Neal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

Annals of Internal Medicine
Paul GlasziouLIPID Study Investigators
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
Katy J L BellDouglas C Bauer
© 2021 Meta ULC. All rights reserved